Biocytogen enters into Bispecific Antibody Drug Conjugate agreement with Radiance Biopharma
The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Jan 24
The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate…
08 Jan 24
In the trial, the vaccine demonstrated non-inferiority to Shingrix as measured by humoral immune response along with reduced…
08 Jan 24
The effectiveness of Zelsuvmi was proven in the B-SIMPLE 4 and B-SIMPLE 2 Phase 3 trials in which…
08 Jan 24
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet…
05 Jan 24
Paragon Healthcare, headquartered in Plano, Texas, offers infusion services to patients via its omnichannel model of ambulatory infusion…
05 Jan 24
Funding allows advancement of diverse programs through multiple clinical data readouts, including multiple indications for lead candidate felzartamab
04 Jan 24
The approval was based on the open-label, single-arm Phase 3 BENEGENE-2 study in which a single dose of…
04 Jan 24
The amendment also consists of an amicable resolution to their commercial dispute and several other adjustments to improve…
04 Jan 24
Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder
02 Jan 24
The late-stage multi-centre, randomised, double-masked, placebo-controlled trial will evaluate the safety and effectiveness of ST-100 ophthalmic solution in…